41例Burkitt淋巴瘤临床特点分析  

Clinical Analysis of 41 Patients with Burkitt's lymphoma

作　　者：丁洁[1] 王立新[2] 赵小利[1] 王利军[1] 李丹丹[1] 姚雨石[1] 于力[1] 

机构地区：[1]解放军总医院血液科,北京100853 [2]海军总医院血液科,北京100048

出　　处：《中国实验血液学杂志》2015年第2期425-430,共6页Journal of Experimental Hematology

摘　　要：目的:探讨Burkitt淋巴瘤的发病特点和临床特征,指导临床治疗和预后评估。方法:对我院2009年1月至2014年6月收治的41例病理诊断为Burkitt淋巴瘤的病例进行回顾性分析。结论:41例患者中,男女比例4.1∶1(33:8);中位年龄13岁(1-67岁);Ⅰ/Ⅱ期18例(43.9%),Ⅲ/Ⅳ期23例(56.1%);常见发病部位为头颈部(23例,56.1%)和腹部(17例,41.5%);合并中枢受累9例(22.0%),骨髓受累9例(22.0%),其中7例(17.1%)转化为急性淋巴细胞白血病L3型;EBV感染率18.8%(3/16例),HBV感染率29.9%(6/38例)。化疗29例,总缓解率93.1%(27/29例),2年总生存率(OS)为83.3%(10/12例);13例患者使用含利妥昔单克隆抗体的成人化疗方案,缓解率92.3%(12/13例),2年OS为66.7%(4/6例)。结论:41例病例特点接近于散发型Burkitt淋巴瘤,但中位发病年龄较小,受累部位以头颈部最常见,含利妥昔单克隆抗体的短疗程高强度化疗能够明显提高成人化疗方案的缓解率,相对地延长生存时间。Objective：To summarize the clinical characteristics of Burkitt＇s lymphoma. 1VIethods：Clinical data of 41 Burkitt＇s lymphoma patients, treated from Jannuary 2009 to June 2014 in Chinese PLA General Hospital, were analyzed retrospectively. Results：Out of the 41 patients, 33 were males and 8 were females, with a median age of 13 （ range, 1 - 67 ）, 18 cases （43.9 % ） were in Ann Arbor stage I / lI, and 23 cases （56.1% ） were in stage Ill/IV. The commonest pathologicalal sites were head and neck （23 cases, 56.1% ）, and then the abdominal （41.5%）, bone marrow （22.0%） and central nervous system （22. 0% ） could also be involved, while 7 cases （ 17.1% ） were patients transformed into acute lymphocytic leukemia-type L3, 18% cases （3/16） were infected by EBV and 29.9% cases （6/ 38） were infected by HBV, 29 cases were treated with chemotherapy, their overal remission rate was 93.1 （27/29 cases）, 2-year overall survival rate （OS） was 83.3% （10/12 cases）; 13 cases were treated with rituximab, their remission rate was 92.3% （ 12/13 cases）, and 2-year OS was 66.7% （4/6 cases）. Conclusion：The 41 cases are more similar to the sporadic Burkitt＇s lymphoma, but the median age of its occurence is more younger, while the most common pathological sites are head and neck, and the short-term and high intensive chemotherapy with rituximab can obviously elevate remission rate for adult patients and larolon~ their survival time.

关 键 词：BURKITT淋巴瘤 临床特点 

分 类 号：R733.1[医药卫生—肿瘤]